A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.

@article{Smith2014API,
  title={A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.},
  author={David Conda Smith and Peter Eisenberg and Georgy Moiseevich Manikhas and Rashmi Chugh and Matthew A. Gubens and Robert Joseph Stagg and Ann M. Kapoun and Lu Gong Xu and Joshua Dupont and Branimir Sikic},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 24},
  pages={
          6295-303
        }
}
PURPOSE This phase I trial evaluated the safety, pharmacokinetics, and pharmacodynamics of demcizumab (OMP-21M18), a humanized IgG2 mAb targeting the Notch ligand DLL4 in adult patients with advanced malignancies. EXPERIMENTAL DESIGN Standard 3+3 design, with demcizumab 0.5, 1, 2.5, or 5 mg/kg weekly or 2.5, 5, or 10 mg/kg every other week, with an expansion cohort at 10 mg/kg every other week. Dose-limiting toxicities (DLT) were assessed during the first 28 days. RESULTS Fifty-five… CONTINUE READING
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

ThecanonicalNotchsignalingpathway : unfolding the activation mechanism

  • IlaganMX KopanR
  • Cell
  • 2009

Similar Papers

Loading similar papers…